Pfizer is a global biopharmaceutical company that develops and manufactures innovative medicines and vaccines to improve health outcomes for people around the world. Renowned for its extensive research and development efforts, Pfizer focuses on various therapeutic areas including vaccines, oncology, immunology, cardiology, endocrinology, and rare diseases. The company is committed to addressing significant health challenges through the discovery of new treatments, leveraging cutting-edge science and technology. Pfizer also emphasizes partnerships and collaborations to expand its capabilities and enhance access to healthcare solutions. Read More
In a hypothetical scenario playing out just last week, leading up to September 27, 2025, Johnson & Johnson (NYSE: JNJ) experienced a significant stock rally, capturing the attention of investors and market analysts alike. While the specifics of such an event remain a forward-looking conjecture, this article delves into the potential
Mumbai, India – September 27, 2025 – Abbott India Limited (NSE: ABBOTINDIA), a prominent player in the Indian pharmaceutical sector, is exhibiting a robust financial trajectory and a promising valuation outlook. Propelled by strong Q1 FY2025-2026 results and strategic market maneuvers, the company continues to solidify its position in the rapidly expanding
As the clock ticks towards midnight on September 30, 2025, the United States government stands on the precipice of a highly imminent and seemingly unavoidable shutdown. With just days left until the new fiscal year begins, partisan gridlock in Congress has stalled all efforts to pass a funding agreement, setting
President Donald Trump‘s proposed 100% tariffs on pharmaceuticals could have a smaller impact than initially expected, thanks to certain loopholes. However, the pharmaceutical industry, particularly Big Pharma, remains displeased.
Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de
The past year hasn't been kind to the stocks featured in this article.
Each has tumbled to their lowest points in 12 months, leaving investors to decide whether they're witnessing fire sales or falling knives.
Rep. Haley Stevens (D-Mich.) announced that she will introduce articles of impeachment against Health and Human Services Secretary Robert F. Kennedy Jr.
A hearing in the Depo-Provera legal action against Pfizer Inc. (NYSE:PFE) will take place on Monday, 29 September at 9:00am CT in the United States Courthouse in Pensacola, Florida. The hearing will address oral arguments from the plaintiffs and defendants concerning the issue of pre-emption. The pre-emption defence is common in drug litigation. It involves the drug manufacturer arguing that they cannot be sued for failure to warn under state law, because changes to a drug warning label are governed by federal law and the FDA. The pre-emption defence asserts that the FDA rejected its request to add a tumour warning to the drug’s label, pre-empting any state law claims that it failed to warn consumers and physicians. The plaintiffs argue that Pfizer’s pre-emption defence fails because the company’s request to the FDA was too broad, because it grouped Depo-Provera with other lower dose hormonal contraceptives, and this led to the FDA’s decision not to approve a tumour warning on the drug’s label in the USA. Also, according to a UN 2022 family planning report, 247 million worldwide are on hormonal contraceptives5,6.
Curious about the most active S&P500 stocks in today's session? Get insights into the stocks that are leading the way in terms of trading volume and market attention.
Pfizer Inc. (NYSE: PFE) will highlight data across its extensive Oncology portfolio at the European Society for Medical Oncology (ESMO) Congress 2025, being held October 17-21 in Berlin, Germany. Data from more than 45 company-sponsored, investigator-sponsored, and collaborative research abstracts, including 11 oral/mini oral presentations and five late-breaking sessions, will be presented across Pfizer’s core scientific modalities and key tumor areas.
The healthcare sector finds itself in turbulent waters in 2025, registering a concerning 5% slump and significantly lagging the overall S&P 500 index. This downturn marks a continuation of a multi-year trend of muted returns for a sector traditionally viewed as defensive and resilient. The underperformance is not merely
